5-Hydroxytryptamine in the cardiovascular system: Focus on the serotonin transporter (SERT)

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 7, 2006, Pages 575-583

  Ni, Wei ^a   Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Serotonin; Serotonin transporter (SERT); Vasoactive agents

Indexed keywords

SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ADRENAL GLAND; BINDING AFFINITY; BIOCHEMISTRY; BIOSYNTHESIS; BLOOD VESSEL; BRAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION; GENETIC ENGINEERING; HEART; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE; HUMAN; KIDNEY; MITOGENESIS; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; RNA TRANSCRIPTION; RNA TRANSLATION; SEROTONIN METABOLISM; SMOOTH MUSCLE; SMOOTH MUSCLE CONTRACTILITY; THROMBOCYTE; THROMBOCYTE AGGREGATION; URINARY EXCRETION;

ANIMALS; CARDIOVASCULAR SYSTEM; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33745124642     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04410.x     Document Type: Review

References (121)

1. Rapport MM Green AA Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J. Biol. Chem. 1948 176 : 1243 51.
2. Nemecek GM Coughlin SR Handley DA Moskowitz MD. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl Acad. Sci. USA 1986 83 : 674 8.
3. Marcos E Adnot S Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003 168 : 487 93.
4. Lee SL Wang WW Fanburg BL. Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J. 2001 15 : 1324 5.
5. Eddahibi S Fabre V Boni C et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ. Res. 1999 84 : 329 36.
6. Wanstall JC Fiore SA Gambino A Chess-Williams R. Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: Effects of exposing rats to hypoxia. Naunyn Schmiedebergs Arch. Pharmacol. 2003 368 : 520 7.
7. Eddahibi E Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: Lessons for the future in pathogenesis. Respir. Res. 2002 3 : 9 12.
8. Eddahibi S Hanoun N Lanfumey L et al. Attenuated hypoxia pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 2000 105 : 1555 62.
9. Maclean MR Deuchar GA Hicks MN et al. Overexpression of the 5-hydroxytryptamine transporter gene. Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004 109 : 2150 5.
10. Eddahibi S Chaouat A Morrell N et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003 108 : 1839 44.
11. Morecroft I Heeley RP Prentice HM Kirk A Maclean MR. 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: Importance of the 5-HT1B receptor. Br. J. Pharmacol. 1999 128 : 730 4.
12. Cooper JR Bloom FE Roth RH. Serotonin (5-hydroxytryptamine), histamine and adenosine. In : The Biochemical Basis of Neuropharmacology. Oxford University Press, New York. 2003 271 320.
13. Walther DJ Bader MA. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 2003 66 : 1673 80.
14. Walther DJ Peter JU Bashammakh S et al. Synthesis of serotonin by a second trytophan hydroxylase isoform. Science 2003 299 : 76.
15. Vanhoutte PM. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J. Cardiovasc. Pharmacol. 1991 17 ( Suppl. 5 S6 12.
16. Kawasaki H Takasaki K. Enhanced 5-hydroxytryptamine release from vascular adrenergic nerves in spontaneously hypertensive rats. Hypertension 1987 10 : 321 7.
17. Hoyer D Clarke DE Fozard JR et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994 46 : 158 203.
18. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin. Invest. Drugs 2003 12 : 805 23.
19. Watts SW. 5-HT in systemic hypertension: Foe, friend or fantasy? Clin. Sci. 2005 108 : 399 412.
20. Tsukamoto K Kurihara T Nakayama N et al. Pressor responses to serotonin injected into the nucleus tractus solitarius of Sprague-Dawley rats and spontaneously hypertensive rats. Clin. Exp. Hypertens. 2000 22 : 63 73.
21. Dalton DW. The cardiovascular effects of centrally administered 5-hydroxytryptamine in the conscious normotensive and hypertensive rat. J. Auton. Pharmacol. 1986 6 : 67 75.
22. Slominski A Pisarchik A Semak I Sweatman T Szczesniewski A Wortsman J. Serotoninergic system in hamster skin. J. Invest. Dermatol. 2002 119 : 934 42.
23. Ikeda K Tojo K Otsubo C et al. 5-Hydroxytryptamine synthesis in HL-1 cells and neonatal rat cardiocytes. Biochem. Biophys. Res. Commun. 2005 328 : 522 5.
24. Cote F Fligny C Fromes Y Mallet J Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 2004 10 : 232 8.
25. Matsumoto M Yoshioka M Togashi H Tochihara M Ikeda T Saito H. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J. Pharmacol. Exp. Ther. 1995 272 : 1044 51.
26. Saxena PR Villalon CM. 5-Hydroxytryptamine: A chameleon in the heart. Trends Pharmacol. Sci. 1991 12 : 223 7.
27. Nebigil CG Maroteaux L. A novel role for serotonin in heart. Trends Cardiovasc. Med. 2001 11 : 329 35.
28. Brattelid T Qvigstad E Lynham JA et al. Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn Schmiedebergs Arch. Pharmacol. 2004 370 : 157 66.
29. Stier CT Itskovitz HD. Formation of serotonin by rat kidneys in vivo. Proc. Soc. Exp. Biol. Med. 1985 180 : 550 7.
30. Moran A Velasco C Martin ML San Roman L. Renal vasoconstrictor response to 5-hydroxytryptamine in the in situ autoperfused rat kidney: Involvement of angiotensin II and the 5-HT2 receptor activation. Eur. J. Pharmacol. 1997 330 : 205 11.
31. Berndt TJ Liang M Tyce GM Knox FG. Intrarenal serotonin, dopamine, and phosphate handling in remnant kidneys. Kidney Int. 2001 59 : 625 30.
32. Delarue C Leboulenger F Morra M et al. Immunohistochemical and biochemical evidence for the presence of serotonin in amphibian adrenal chromaffin cells. Brain Res. 1988 459 : 17 26.
33. Verhofstad AA Jonsson G. Immunohistochemical and neurochemical evidence for the presence of serotonin in the adrenal medulla of the rat. Neuroscience 1983 10 : 1443 53.
34. Fernandez-Vivero J Rodriguez-Sanchez F Verastegui C Cordoba Moriano F Romero A de Castro JM. Immunocytochemical distribution of serotonin and neuropeptide Y (NPY) in mouse adrenal gland. Histol. Histopathol. 1993 8 : 509 20.
35. Delarue C Becquet D Idres S Hery F Vaudry H. Serotonin synthesis in adrenochromaffin cells. Neuroscience 1992 46 : 495 500.
36. Orso E Szalay KS Toth IE et al. Effect of histamine on corticosteroid secretion of isolated human and rat adrenocortical cells. Inflamm. Res. 1995 44 : S48 9.
37. Hinson JP Vinson GP Pudney J Whitehouse BJ. Adrenal mast cells modulate vascular and secretory responses in the intact adrenal gland of the rat. J. Endocrinol. 1989 121 : 253 60.
38. Lefebvre H Compagnon P Contesse V et al. Production and metabolism of serotonin (5-HT) by the human adrenal cortex: Paracrine stimulation of aldosterone secretion by 5-HT. J. Clin. Endocrinol. Metab. 2001 86 : 5001 7.
39. Lefebvre H Contesse V Delarue C et al. Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: In vivo and in vitro studies. J. Clin. Endocrinol. Metab. 1993 77 : 1662 6.
40. Rocco S Ambroz C Aguilera G. Interaction between serotonin and other regulators of aldosterone secretion in rat adrenal glomerulosa cells. Endocrinology 1990 127 : 3103 10.
41. Lefebvre H Contesse V Delarue C et al. The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man. J. Clin. Endocrinol. Metab. 1995 80 : 504 7.
42. Lefebvre H Gonzalez KN Contesse V Delarue C Vaudry H Kuhn JM. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocr. Res. 1998 24 : 749 52.
43. Sugimoto Y Yamada J Yoshikawa T Nishikaw F Noma T Horisaka K. The involvement of serotonin in the catecholamine release from the adrenal medulla. Adv. Exp. Med. Biol. 1996 398 : 561 3.
44. Yildiz O Smith JR Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci. 1998 62 : 1723 32.
45. Watts SW. 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension 2000 35 : 244 8.
46. Martin GR. Vascular receptors for 5-hydroxytryptamine: Distribution, function and classification. Pharmacol. Ther. 1994 62 : 283 324.
47. McDuffie JE Motley ED Limbird LE Maleque MA. 5-Hydroxytryptamine stimulates phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures. J. Cardiovasc. Pharmacol. 2000 35 : 398 402.
48. Hoffman BJ Mezey E Brownstein MJ. Cloning of a serotonin transporter affected by antidepressants. Science 1991 254 : 579 80.
49. Blakely RD Berson HE Fremeau RT et al. Cloning and expression of a functional serotonin transporter from rat brain. Nature 1991 354 : 66 70.
50. Ramamoorthy S Bauman AL Moore KR et al. Antidepressant and cocaine-sensitive human serotonin transporter: Molecular cloning, expression and chromosomal localization. Proc. Natl Acad. Sci. USA 1993 90 : 2542 6.
51. Chang AS Chang SM Starnes DM Schroeter S Bauman AL Blakely RD. Cloning and expression of the mouse serotonin transporter. Brain Res. Mol. Brain Res. 1996 43 : 185 92.
52. Chen NH Reith MEA. Structure-function relationships for biogenic amine neurotransmitter transporters. In : Reith MEA (ed.). Contemporary Neuroscience: Neurotransmitter Transporters, Functional and Regulation, 2nd edn. Humana Press, Totowa. 2002 53 109.
53. Ramammoorthy S. Regulation of monoamine transporters: Regulated phosphorylation, dephosphorylation and trafficking. In : Reith MEA (ed.). Contemporary Neuroscience: Neurotransmitter Transporters, Functional and Regulation, 2nd edn. Humana Press, Totowa. 2002 1 23.
54. Kilic F Rudnick G. Oligomerization of the serotonin transporter and its functional consequences. Proc. Natl Acad. Sci. USA 2000 97 : 3106 11.
55. Schmid JA Just H Sitte HH. Impact of oligomerization on the function of the human serotonin receptor. Biochem. Soc. Trans. 2001 29 : 732 6.
56. Ozaslan D Wang S Ahmed BA et al. Glycosyl modification facilitates homo- and hetero-oligomerization of the serotonin transporter. A specific role for sialic acid residues. J. Biol. Chem. 2003 278 : 43 91 4000.
57. Kocabas AM Rudnick G Kilic F. Functional consequences of homo- but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters. J. Neurochem. 2003 85 : 1513 20.
58. Schmid JA Scholze P Kudlacek O Freissmuth M Singer EA Sitte HH. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J. Biol. Chem. 2001 276 : 3805 10.
59. Galli A Petersen CI deBlaquiere M Blakely RD De Felice LJ. Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin gated channel. J. Neurosci. 1997 17 : 3401 11.
60. Walther DJ Peter JU Winter S et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell 2003 115 : 851 62.
61. Griffin M Casadio R Bergamini CM. Transglutaminases: Nature's biological glues. Biochem. J. 2002 368 : 377 96.
62. Rothman RB Ayestas MA Dersch CM Baumann MH. Aminorex, fenfluramine, chlorphentermine are serotonin transporter substrates; implications for primary pulmonary hypertension. Circulation 1999 100 : 869 75.
63. Abenhaim L Moride Y Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 1996 355 : 609 16.
64. Connolly HM Crary JL Mcgood MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997 337 : 581 8.
65. Rudnick G Wall SC. The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl Acad. Sci. USA 1992 89 : 1817 21.
66. Mlinar B Corradetti R. Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur. J. Neurosci. 2003 18 : 1559 71.
67. Ramamoorthy S Giovanetti E Qian Y Blakely RD. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J. Biol. Chem. 1998 273 : 2458 66.
68. Blakely RD Ramamoorthy S Schroeter S et al. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry 1998 44 : 169 78.
69. Samuvel DJ Jayanthi LD Bhat NR Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: Evidence for distinct cellular mechanisms involved in transporter surface expression. J. Neurosci. 2005 25 : 29 41.
70. Heils A Teufel A Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 1996 66 : 2621 4.
71. Murphy DL Lerner A Rudnick G Lesch KP. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol. Interv. 2004 4 : 109 23.
72. Mortensen OV Kristensen AS Rudnick G Wiborg O. Molecular cloning, expression and characterization of a bovine serotonin transporter. Mol. Brain Res. 1999 71 : 120 6.
73. Ni W Thompson J Northcott C Lookingland K Watts SW. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J. Cardiovasc. Pharmacol. 2004 43 : 770 81.
74. Huang J Pickel VM. Serotonin transporters (SERTs) within the rat nucleus of the solitary tract: Subcellular distribution and relation to 5-HT2A receptors. J. Neurocytol. 2002 31 : 667 79.
75. Schroeter S Levey AL Blakely RD. Polarized expression of antidepressant sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Mol. Cell. Neurosci. 1997 9 : 170 84.
76. Armando I Tjurmina OA Li Q Murphy DL Saavedra JM. The serotonin transporter is required for stress-evoked increases in adrenal catecholamine synthesis and angiotensin II AT(2) receptor expression. Neuroendocrinology 2003 78 : 217 25.
77. Morecroft I Loughlin L Nilsen M et al. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J. Pharmacol. Exp. Ther. 2005 313 : 539 48.
78. Gonzalez AM Smith AP Emery CJ Higenbottam TW. The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence. Am. J. Respir. Cell Mol. Biol. 1998 19 : 245 9.
79. Wanstall JC Fiore SA Gambino A Chess-Williams R. Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: Effects of exposing rats to hypoxia. Naunyn Schmiedebergs Arch. Pharmacol. 2003 368 : 520 7.
80. Weir EK Reeve HL Huang JM et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstrction. Circulation 1996 94 : 2216 20.
81. Desta B Steed S Ravel D Laudignon N Vanhoutte PM Boulanger CM. Acute and chronic effects of dexfenfluramine on the porcine pulmonary artery. Gen. Pharmacol. 1998 30 : 403 10.
82. Barman SA Isales CM. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1. Pulm. Pharmacol. Ther. 1999 11 : 183 7.
83. Hong Z Olschewski A Reeve HL Nelson DP Hong F Weir EK. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am. J. Physiol. Lung Cell Mol. Physiol. 2004 286 : L531 8.
84. Greenberg BD Tolliver TJ Huang S-J Li Q Bengel D Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 1999 88 : 83 7.
85. Bengel D Murphy DL Andrews AM et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('ecstasy') in serotonin transporter deficient mice. Mol. Pharmacol. 1998 53 : 649 55.
86. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular disease: A platelet connection. Cell Mol. Life Sci. 2005 62 : 159 70.
87. Kurne E Ertugrul A Anil Yagcioglu AE Yazici KM. Venous thromobembolism and escilatolopram. Gen. Hosp. Psychiatry 2004 26 : 481 3.
88. Isbister GK Bowe SJ Dawson A Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J. Toxicol. Clin. Toxicol. 2004 42 : 277 85.
89. Degner D Grohmann R Kropp S et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program MSP. Pharmacopsychiatry 2004 37 ( Suppl. 1 S39 45.
90. Ray WA Meredith S Thapa PB Hall K Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin. Pharmacol. Ther. 2004 75 : 234 41.
91. Khawaja IS Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis. 2003 5 : 153 60.
92. Cohen HW Gibson G Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am. J. Med. 2000 108 : 2 8.
93. Settle EC. Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J. Clin. Psychiatry 1998 59 : 25 30.
94. Kelly CA Dhaun N Laing WJ Strachan FE Good AM Bateman DN. Comparative toxicity of citalopram and the newer antidepressants after overdose. J. Toxicol. Clin. Toxicol. 2004 42 : 67 71.
95. Pacher P Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr. Pharm. Des. 2004 10 : 2463 75.
96. Pacher P Ungvari Z Nanasi PP Furst S Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr. Med. Chem. 1999 6 : 469 80.
97. Pacher P Ungvari Z Kecskemeti V Furst S. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr. Med. Chem. 1998 5 : 381 90.
98. Tomita T Umegaki K Hayashi E. Hypoaggregability of washed platelets from stroke-prone spontaneously hypertensive rats (SHRSP). Stroke 1984 15 : 70 5.
99. Umegaki K Ichikawa T. Vitamin E did not prevent platelet activation, but prevented increase of lipid peroxides and renal dysfunction in DOCA-salt hypertensive rats. J. Nutr. Sci. Vitaminol. 1993 39 : 437 49.
100. Ding YA Chou TC Huan R. Are platelet cytosolic free calcium, serotonin concentration and blood viscosity different between hypertensive and normotensive subjects? Cardiology 1994 85 : 76 81.
101. Kamal LA Le Quan-Bui KH Meyer P. Decreased uptake of 3H-serotonin and endogenous content of serotonin in blood platelets in hypertensive patients. Hypertension 1984 6 : 568 73.
102. Lazartigues E Brefel-Courbon C Bagheri H et al. Fluoxetine-induced pressor response in freely moving rats: A role for vasopressin and sympathetic tone. Fundam. Clin. Pharmacol. 2000 14 : 443 51.
103. Amsterdam JD Garcia-Espana F Fawcett J et al. Blood pressure changes during short term fluoxetine. J. Clin. Psychopharmacol. 1999 19 : 9 14.
104. Tsai ML Lin MT. Hypertension and tachycardia produced by inhibition of reuptake of 5-hydroxytryptamine by fluoxetine in the rat. Neuropharmacology 1986 25 : 799 802.
105. Grubb BP Samoil D Kosinski D Wolfe D Lorton M Madu E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am. J. Med. 1994 97 : 366 8.
106. Bergeron L Boule M Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann. Pharmacother. 2005 39 : 956 61.
107. Skop BF Finkelstein JA Mareth TR Magoon MR Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am. J. Emerg. Med. 1994 12 : 642 4.
108. Mason P Morris VA Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000 79 : 201 9.
109. Dalfen AK Stewart DE. Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can. J. Psychiatry 2001 46 : 258 63.
110. Wassertheil-Smoller S Shumaker S Ockene J et al. Depression and cardiovascular sequela in postmenopausal women: The Women's Health Initiative (WHI). Arch. Intern. Med. 2004 164 : 289 98.
111. Hoefgen B Schulze TG Ohlraun S et al. The power of sample size and homogenous sampling: Association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol. Psychiatry 2005 57 : 247 51.
112. Plante GE. Depression and cardiovascular disease: A reciprocal relationship. Metabolism 2005 54 : 45 8.
113. Cohen HW Madhavan S Alderman MH. History of treatment for depression: Risk factor for myocardial infarction in hypertensive patients. Psychosom. Med. 2001 63 : 203 9.
114. Rafanelli C Roncuzzi R Milaneschi Y et al. Stressful life events, depression and demoralization as risk factors for acute coronary heart disease. Psychother. Psychosom. 2005 74 : 179 84.
115. Fumeron F Betoulle D Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de I'Infarctus du Myocarde (ECTIM). Circulation 2002 105 : 2943 5.
116. Sauer WH Berlin JA Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003 108 : 32 6.
117. Schlienger RG Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: Can they prevent acute myocardial infarction? Am. J. Cardiovasc. Drugs 2003 3 : 149 62.
118. Paczkowski FA Bryan-Lluka LJ Porzgen P Bruss M Bonish H. Comparison of the pharmacological properties of cloned rat, human and bovine norepinephrine transporters. J. Pharmacol. Exp. Ther. 1999 290 : 761 7.
119. Chen JJ Li Z Pan H et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 2001 21 : 6348 61.
120. Martel F Azevedo I. An update on the extraneuronal monoamine transporter (EMT) characteristics, distribution and regulation. Curr. Drug Metab. 2003 4 : 313 18.
121. Horvath G Sutto Z Torbati A Conner GE Salathe M Wanner A. Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2003 285 : L829 37.